'In briefing documents published ahead an advisory committee meeting, FDA staffers argue that in metastatic castration-resistant prostate cancer (mCRPC), Lynparza has only showed a favorable benefit-risk profile in patients with BRCA mutations.'

https://www.fiercepharma.com/pharma/fda-argues-astrazeneca-mercks-lynparza-only-works-prostate-cancer-subset